Podcasts about suny upstate medical university

In this episode, Dr. Andy Cutler talks with Dr. Bhagwan Bahroo about nutritional interventions in psychiatry, including diet, supplements, metabolic health, inflammation, and the gut-brain axis. They explore where the evidence is strongest, where hype outpaces the data, and how clinicians can discuss nutritional strategies as adjunctive tools without losing focus on core treatments.  Bhagwan A. Bahroo, MD, DLFAPA, is a board-certified psychiatrist in adult, addiction, and forensic psychiatry and an Assistant Professor at the Uniformed Services University of the Health Sciences in Bethesda, Maryland. He has extensive clinical experience at Walter Reed National Military Medical Center and has worked in interventional psychiatry, including TMS and esketamine, with an interest in nutrition and its role in mental health.   Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.   Fall Congress   Get $100 off NEI Fall Congress registration with code POD26. Go to https://nei.global/fall to sign up today!   Never miss an episode!

In this episode of PsychopharmaPearls, Dr. Andy Cutler talks with Dr. Leslie Citrome about akathisia, a common but often misdiagnosed antipsychotic side effect that can look like agitation, anxiety, irritability, or worsening psychiatric symptoms. They discuss how to recognize akathisia in clinical practice, distinguish it from true agitation, identify key timing and symptom clues, and avoid common treatment mistakes, including why benztropine is not an appropriate treatment for akathisia.  Leslie Citrome, MD, MPH, is Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College and an internationally recognized expert in psychopharmacology and clinical trial interpretation. He has authored more than 600 scientific publications and frequently lectures on applying research findings to real-world psychiatric practice.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.   Fall Congress   Get $100 off NEI Fall Congress registration with code POD26. Go to https://nei.global/fall to sign up today!   Never miss an episode!

In this episode, Dr. Andy Cutler speaks with Dr. Neill Epperson about how to evaluate cognitive complaints in women. They discuss how to differentiate between ADHD, hormonal changes (such as perimenopause), mood and anxiety disorders, and age-related cognitive decline. The conversation highlights key clinical clues, including symptom timing and fluctuation, to improve diagnostic accuracy. Practical strategies for assessment and treatment are reviewed to help clinicians make more informed, individualized decisions.   C. Neill Epperson, MD, is the Robert Freedman Endowed Professor and Chair of the Department of Psychiatry at the CU Anschutz School of Medicine. She is an internationally recognized expert in women's mental health, with research focused on the effects of hormonal transitions—such as puberty, pregnancy, and menopause—on mood, cognition, and psychiatric disorders.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Never miss an episode!

In this episode, Dr. Andy Cutler speaks with Dr. Thomas Schwartz about insomnia related to antidepressant discontinuation, including how rebound and withdrawal symptoms can emerge when tapering or stopping treatment. They review the underlying mechanisms, clinical risk factors, and how to distinguish discontinuation-related insomnia from relapse of depression or primary sleep disorders. The discussion emphasizes practical, evidence-informed strategies for safely tapering antidepressants and managing sleep disturbance in psychiatric practice.   Thomas L. Schwartz, MD, is a Distinguished Teaching Professor at Norton College of Medicine, SUNY Upstate Medical University in Syracuse, New York. He is an award-winning educator deeply involved in medical student and resident training, as well as the development of continuing medical education in psychiatry.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Save $100 on registration for 2026 NEI Spring Congress with code NEIPOD26  Register today at nei.global/spring  Never miss an episode!

In this episode of The Dream Journal, host Katherine Bell speaks with dreamwork pioneer Robert Bosnak, founder of Embodied Imagination, about how to work with dreams, symptoms, memories, and trauma without forcing interpretation. Bosnak shares why “not knowing” can be the most skillful stance in dreamwork, how to re-enter a dream through flashback memory, and how shifting perspective—from the “narrator” to the environment or other beings—can unlock relief, agency, and integration. Keywords: dreamwork, embodied imagination, Robert Bosnak, Katherine Bell, experiential dreamwork, flashback memory, non-interpretive dreamwork, trauma nightmares, somatic symptoms, neutral witness, psychedelic integration, imaginal realm, dual consciousness Key takeaways Start with not knowing. A dream can be meaningful even when you can't explain it; “not understanding” can keep you closer to the living experience of the dream. Re-enter the dream as a place. Instead of treating dreams as stories to decode, Embodied Imagination uses flashback memory to return to the dream environment and feel it in the body. The body leads the mind. Sensation and affect often arrive before conscious meaning—so the work begins with what the body is already doing. Work with symptoms as imagery. By focusing attention on the location of a symptom, spontaneous images can arise (distinct from mental “fabrication”). Shift perspective to create change. Moving from the “I/narrator” to the viewpoint of the image (e.g., the mountains, a closet, a wall) can soften overwhelm and open new possibilities. Use a neutral witness for trauma. Approaching a traumatic scene from the perspective of a steady object in the environment can reduce re-traumatization while allowing the experience to be processed. Dual consciousness supports integration. In psychedelic or numinous states, holding “two worlds at once” helps you stay grounded while engaging the imaginal reality. Integration is a practice. Returning to the experience, slowing it down, and revisiting it from multiple perspectives can turn a peak moment into an embodied daily exercise. BIO: Robert Bosnak is a Zurich-trained Jungian psychoanalyst specializing in dreaming. He founded Embodied Imagination and is a past IASD president, a fiction and non-fiction book author, and psychiatry faculty at the SUNY Upstate Medical University. He is also presenting at the IASD conference in June up in Ashland Oregon. Learn more at EmbodiedImagination.com To donate to the show’s host community radio station, go to KSQD.org The IASD conference is June 13-17 in Ashland Oregon. Find out more at IASDconferences.org/2026/ SHARE A DREAM FOR THE SHOW or a question or enquire about being a guest on the podcast by emailing Katherine Bell at katherine@ksqd.org. Follow on LI, IG, YT, FB, & LT @ExperientialDreamwork #thedreamjournal. To learn more or to inquire about exploring your own dreams go to ExperientialDreamwork.com. This show, episode number 359, was recorded during a live broadcast on April 18, 2026 at KSQD.org, community radio of Santa Cruz. Videos available on YouTube at youtube.com/@experientialdreamwork. Popular playlists: “Dream Journal shorts” and “FULL LENGTH VIDEOS”. Here are links to some other Dream Journal episodes you might be interested in: Dancing With Dreams & Nightmares | Ritual Dreamwork, Bees, Snakes, & the Dream Hive with Lana Nasser From Shame to Self-Love with Bill St. Cyr Intro and outro music by Mood Science. Ambient music new every week by Rick Kleffel. Archived music can be found at Pandemiad.com. Many thanks to Rick for also engineering the show and to Erik Nelson for answering the phones. SHARE A DREAM FOR THE SHOW or a question or enquire about being a guest on the podcast by emailing Katherine Bell at katherine@ksqd.org. Follow on LI, IG, YT, FB, & LT @ExperientialDreamwork #thedreamjournal. To learn more or to inquire about exploring your own dreams go to ExperientialDreamwork.com. The Dream Journal aims to: Increase awareness of and appreciation for nightly dreams. Inspire dream sharing and other kinds of dream exploration as a way of adding depth and meaningfulness to lives and relationships. Improve society by the increased empathy, emotional balance, and sense of wonder which dream exploration invites. A dream can be meaningful even if you don’t know what it means. The Dream Journal is produced at and airs on KSQD Santa Cruz, 90.7 FM. Catch it streaming LIVE at KSQD.org 10-11am Pacific Time on Saturdays. Call or text with your dreams or questions at 831-900-5773 or email at onair@ksqd.org. Podcasts are available on all major podcast platforms the Monday following the live show. The complete KSQD Dream Journal podcast page can be found at ksqd.org/the-dream-journal/. Thanks for being a Dream Journal listener! Available on all major podcast platforms. Rate it, review it, subscribe, and tell your friends.

In this episode, Dr. Andy Cutler speaks with Dr. Holly Swartz about the critical role of sleep and circadian rhythms in bipolar disorder, including how sleep disturbance can function as both a symptom and trigger of mood episodes. They discuss how clinicians can better assess sleep to identify early warning signs of relapse, along with practical strategies for intervention, including applying principles of Interpersonal and Social Rhythm Therapy (IPSRT), choosing between behavioral and pharmacologic treatments for insomnia, and avoiding sleep medications that may destabilize mood. The episode offers a clinically focused approach to improving relapse prevention through better sleep management.   Holly A. Swartz, MD, is Professor of Psychiatry at the University of Pittsburgh, Director of the Center for Advanced Psychotherapy, and Medical Director of the Depression and Manic Depression Prevention Program. An internationally recognized expert in bipolar disorder treatment, she is President of the International Society for Bipolar Disorders and known for advancing Interpersonal and Social Rhythm Therapy (IPSRT), an evidence-based approach targeting sleep, circadian rhythms, and mood stabilization to prevent relapse.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Resources  The Social Rhythm Therapy Workbook for Bipolar Disorder  Bipolar II Disorder  Interpersonal and Social Rhythm Therapy – ipsrt.org  Depression and Bipolar Support Alliance – dbsalliance.org    Save $100 on registration for 2026 NEI Spring Congress with code NEIPOD26  Register today at nei.global/spring    Never miss an episode!

Dr. Somer Delsignore, DNP, is a Doctor of Nursing Practice and board-certified pediatric nurse practitioner specializing in complex chronic illness in children. Her clinical work focuses on the diagnosis and management of immune dysfunction using a root-cause approach. She developed the R.E.S.E.T. Protocol using a Root Cause lens to treat Immune Dysfunction systematically. A fellow of MAPS and AAOT and a member of ILADS, her expertise includes autoimmune, neuroimmune, and psychiatric manifestations of infectious diseases, especially tick-borne illnesses, as well as links to Autism Spectrum Disorder, PANS/PANDAS, and autoimmune encephalopathy. Delsignore completed her graduate and doctoral training at the University of Pennsylvania and SUNY Upstate Medical University, graduating magna and summa cum laude, and trained at leading pediatric centers, including  Children's Hospital of Philadelphia (CHOP), Penn State Children's, and Children's Health in Dallas. She is the CEO and Founder of Hudson Valley Integrative Health in Beacon, New York.

In this episode, Dr. Andy Cutler talks with Dr. Robert Cotes about optimizing outcomes in early psychosis and why the first episode is a critical window for intervention. They discuss the impact of duration of untreated psychosis, recovery trajectories after a first episode, and what to measure beyond symptom reduction—including functional outcomes, cognition, and relapse risk. The conversation also highlights strategies for engaging young adults and families in coordinated specialty care, early identification of clinical high risk for psychosis, and innovations aimed at improving long-term recovery.  Robert O. Cotes, MD, is Professor of Psychiatry and Behavioral Sciences at Emory University School of Medicine and Chief of Psychiatry at Grady Health System in Atlanta. He directs the Clinical and Research Program for Psychosis at Grady, which includes Project ARROW, a coordinated specialty care program for young people with early psychosis, and a specialized clozapine clinic for treatment-resistant schizophrenia.    Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Save $100 on registration for 2026 NEI Spring Congress with code NEIPOD26  Register today at nei.global/spring  Never miss an episode!

March is International Women's Month. My guest is Bergen County-based sculptor Carolyn D. Palmer for her newest project honoring Dr. Elizabeth Blackwell, the first female physician in the U.S., and Dr. Sarah Loguen Fraser, the first African American woman to graduate from SUNY Upstate Medical University. The statues stand together in the courtyard of SUNY Upstate Medical University.See omnystudio.com/listener for privacy information.

PsychopharmaPearls is NEI's focused podcast series highlighting the clinical insights that can sharpen your prescribing decisions. In this episode, Dr. Andy Cutler talks with Dr. Lisa Harding about how to choose between IV ketamine and intranasal esketamine for patients with difficult-to-treat depression. They unpack the differences that truly matter in practice—from patient selection and monitoring to access, cost, and common missteps. Tune in for practical pearls you can immediately apply to select the right treatment for the right patient.  Lisa Harding, MD is a board-certified psychiatrist and nationally recognized depression specialist with deep expertise in interventional psychiatry. She has performed more than 4,000 procedures, including electroconvulsive therapy (ECT), intravenous ketamine, intranasal esketamine, and transcranial magnetic stimulation (TMS). Dr. Harding is known for her thoughtful approach to complex, treatment-resistant depression, integrating advanced somatic therapies, psychopharmacology, and psychotherapy. She serves as an Assistant Clinical Professor of Psychiatry at Yale University in New Haven, Connecticut.  Andrew J. Cutler, MD is a leading psychiatrist, psychopharmacology expert, and clinical researcher with decades of experience in CNS drug development. As Chief Medical Officer of Neuroscience Education Institute and EMA Wellness, he brings frontline clinical insight together with deep knowledge of the evidence base. Dr. Cutler is widely recognized for translating research into practical guidance for everyday practice and serves as a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Resources  Sanacora G et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry 2017;74(4):399-405. doi:10.1001/jamapsychiatry.2017.0080  McIntyre RS et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. Am J Psychiatry 2021;178(5):383-399. doi:10.1176/appi.ajp.2020.20081251    Save $100 on registration for 2026 NEI Spring Congress with code NEIPOD26  Register today at nei.global/spring    Never miss an episode!

Send a textHow can patients and providers trust AI in healthcare if they don't understand how it works? In this clip from our episode "Making Healthcare Access Truly Borderless”, HealthBiz Podcast host David Williams speaks with Dr. Sarah Matt, author of The Borderless Healthcare Revolution, about why explainability and trust matter when AI is used in care delivery.Listen to the full episode here

Send a textHealthcare access is often treated as a technology problem, but the real barriers run much deeper. Geography, cost, culture, trust, and digital readiness all shape whether patients can actually get the care they need. Without addressing the system as a whole, even the most advanced tools risk leaving people behind.Sarah Matt, Author of The Borderless Healthcare Revolution, joins the HealthBiz Podcast to discuss what it truly takes to break down geographic barriers in healthcare, why access must be designed into systems from the start, and how technology can support care without replacing the human connection at its core. 

In this episode, Dr. Andy Cutler talks with Dr. Tim Wilens about enduring myths surrounding ADHD diagnosis and treatment, beginning with why misconceptions about overdiagnosis and misuse continue to shape clinical hesitation. They explore common misunderstandings about ADHD medications—including stimulants versus non-stimulants, concerns about diversion, personality changes, and long-term safety—and contrast stigma-driven narratives with the clinical evidence. The conversation equips clinicians with practical, evidence-based strategies to address patient fears, counter misinformation, and make thoughtful, individualized treatment decisions.  Timothy Wilens, MD, is chief of the Division of Child and Adolescent Psychiatry and is co-director of the Center for Addiction Medicine at Massachusetts General Hospital. He is the MGH Trustees Chair in Addiction Medicine and a professor of psychiatry at Harvard Medical School. Dr. Wilens' research interests include the relationship among attention deficit/hyperactivity disorder (ADHD), bipolar disorder, and substance use disorders, embedded health care models, and the pharmacotherapy of ADHD across the lifespan.   Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Save $100 on registration for 2026 NEI Spring Congress with code NEIPOD26  Register today at nei.global/spring  Never miss an episode!

Join us this week as Dr. Jay and Brad interview their guest, Dr. Sara Matt.Sara Matt, MD, MBA, is a surgeon turned health technology strategist, author, and speaker. Her work focuses on how digital tools, from remote surgery to telemedicine to AI, can expand access to healthcare and eliminate the traditional boundaries that separate patients from care.With over two decades of experience at the intersection of medicine and innovation, Dr. Matt has held leadership roles at Oracle Health, NextGen, and multiple health tech startups. She has designed and deployed systems that reach patients around the world, including hard-to-serve and underserved populations.A practicing physician, Dr. Matt continues to treat patients in rural and charity-based settings, keeping her closely connected to the human side of healthcare access. She speaks widely at healthcare and technology conferences and has appeared on national panels about artificial intelligence, care delivery reform, and digital transformation.A graduate of Cornell, SUNY Upstate Medical University, and UT Austin's McCombs School of Business, she blends clinical acumen with deep technical knowledge to challenge the status quo and to reimagine what healthcare can look like when geography no longer dictates your care.To contact Dr. Sara Matt, visit her website at drsaramatt.com or connect with her on LinkedIn at https://www.linkedin.com/in/sarahmattmd/.

In this episode, Robert Corona, DO, MBA, FCAP, FASCP, John B. Henry Professor of Pathology and Chief Executive Officer at SUNY Upstate Medical University Hospital, joins the podcast to discuss reducing workplace violence, easing administrative burden through new technologies, and improving pathology operations with innovations such as drone-based transportation. He also shares where he sees opportunities for organizational growth as healthcare systems adapt to new operational and workforce challenges.

In this episode, Dr. Andy Cutler speaks with Dr. Jonathan Meyer to dispel common myths about antipsychotic treatment, from concerns about sedation, personality change, and brain effects to misunderstandings about safety, long-acting injectables, and clozapine. The discussion focuses on what the evidence actually shows about efficacy, risk, and recovery, and how clinicians can communicate more clearly and confidently with patients and families.  Jonathan Meyer, MD, DLFAPA, is a Voluntary Clinical Professor of Psychiatry at the University of California, San Diego. He serves as a Senior Academic Advisor to the California Department of State Hospitals, is a psychopharmacology consultant to the first episode psychosis program at Balboa Naval Medical Center, and has published extensively on psychopharmacology, including co-authoring The Clozapine Handbook, The Clinical Use of Antipsychotic Plasma Levels, and The Lithium Handbook with Dr. Stephen Stahl.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Save $100 on registration for 2026 NEI Spring Congress with code NEIPOD26  Register today at nei.global/spring  Never miss an episode!

This episode's Community Champion Sponsor is Ossur. To learn more about their ‘Responsible for Tomorrow' Sustainability Campaign, and how you can get involved: CLICK HEREEpisode Overview: Geography should never determine whether a patient lives or dies.Our next guest, Dr. Sarah Matt, is on a mission to make that vision a reality.A surgeon turned health technology strategist, Sarah has spent over two decades breaking down the barriers that separate patients from care.From leading Oracle's $28 billion Cerner integration to architecting the first U.S. remote robotic surgery network, she's been at the forefront of healthcare's digital transformation.Now, as a national bestselling author of The Borderless Healthcare Revolution, Sarah is equipping healthcare leaders with a practical framework to eliminate physical, financial, cultural, digital, and trust barriers to care.Join us to discover how we can build a truly borderless healthcare system. Let's go!Episode Highlights:Five Pillars of Access: Physical, financial, cultural, digital, and trust barriers—with cultural and trust most overlookedFrom Bedside to Billions: Sarah left the OR to impact millions through technology instead of 20 patients a day2026 is the Year of Catch Up: Fix data governance and interoperability before AI can deliver real resultsActionable Over Theoretical: Every chapter includes a builder's box and checklist for immediate actionNew Leadership Required: Leaders must think faster, embrace uncertainty, and operate in the gray zoneAbout our Guest:Sarah Matt, MD, MBA, is a surgeon turned health technology strategist, author, and speaker. Her work focuses on how digital tools, from remote surgery to telemedicine to AI, can expand access to healthcare and eliminate the traditional boundaries that separate patients from care.With over two decades of experience at the intersection of medicine and innovation, Dr. Matt has held leadership roles at Oracle Health, NextGen, and multiple health tech startups. She has designed and deployed systems that reach patients around the world, including hard-to-serve and underserved populations.A practicing physician, Dr. Matt continues to treat patients in rural and charity-based settings, keeping her closely connected to the human side of healthcare access. She speaks widely at healthcare and technology conferences and has appeared on national panels about artificial intelligence, care delivery reform, and digital transformation. She is also the author of The Borderless Healthcare Revolution: The Definitive Guide to Breaking Geographic Barriers Through Technology.A graduate of Cornell University, SUNY Upstate Medical University and UT Austin's McCombs School of Business, she blends clinical acumen with deep technical knowledge to challenge the status quo and to reimagine what healthcare can look like when geography no longer dictates your care.Links Supporting This Episode: Dr. Sarah Matt Website: CLICK HERE

In this episode, Dr. Andy Cutler and Dr. Jeff Strawn unpack common misconceptions that complicate real-world use of antidepressants. They review evidence on efficacy, suicidality risk, mechanisms, and early side effects, and discuss how to navigate hesitancy and misinformation. The conversation also addresses when to start medication, how to balance caution with timely intervention in youth, and practical ways to strengthen trust and therapeutic alliance.  Jeffrey R. Strawn, MD, FAACAP, is a Professor of Psychiatry, Pediatrics, and Clinical & Translational Pharmacology at the University of Cincinnati (UC) in Cincinnati, Ohio. He is the Director of the UC Anxiety Disorders Research Program and the Associate Vice Chair of Research in the Department of Psychiatry & Behavioral Neuroscience at UC.   Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Resources  Zhang K et al. Functional connectivity predicting transdiagnostic treatment outcomes in internalizing psychopathologies. JAMA Netw Open 2025;8(9):e2530008. doi: 10.1001/jamanetworkopen.2025.30008  Lagerberg T et al. Selective serotonin reuptake inhibitors and suicidal behaviour: a population-based cohort study. Neuropsychopharmacology 2022;47(4):817-23. doi: 10.1038/s41386-021-01179-z  Never miss an episode!

As 2025 comes to an end, we revisit our most downloaded episode of the year. Join Dr. Andy Cutler and Dr. Carla Sharp as they explore the current conceptualization of borderline personality disorder (BPD), including diagnostic challenges, evidence-based treatments, and strategies to reduce stigma by framing BPD as a treatable condition. The conversation also highlights recent updates to the APA's BPD guidelines and what they mean for clinical practice.  Carla Sharp, PhD is a distinguished clinical psychologist specializing in developmental psychopathology, particularly borderline personality disorder (BPD). She is a professor in the Clinical Psychology Doctoral Program and serves as the Associate Dean for Faculty and Research at the University of Houston. Additionally, she directs both the Adolescent Diagnosis, Assessment, Prevention, and Treatment Center and the Developmental Psychopathology Lab at the university.    Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Never miss an episode!

Join Drs. Andy Cutler and Roger McIntyre as they discuss the most significant advancements in psychopharmacology over the past year. Their conversation highlights groundbreaking developments and innovations in the field of psychiatry.   Roger McIntyre, MD, FRCPC, is a globally recognized psychiatrist and psychopharmacologist who holds pivotal roles in academia, research, and leadership. His research primarily focuses on the phenomenology, neurobiology, and development of novel therapeutics for mood disorders. Dr. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto.   Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Resources  Thanarajah ES et al. Soft drink consumption and depression mediated by gut microbiome alterations. JAMA Psychiatry 2025;82(11):1095–1102. doi:10.1001/jamapsychiatry.2025.2579  Durgam S et al. Lumateperone as adjunctive therapy in patients with major depressive disorder: results from a randomized, double-blind, phase 3 trial. J Clin Psychiatry 2025;86(4):25m15848. doi: 10.4088/JCP.25m15848  Hendershot CS et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry 2025;82(4):395–405. doi: 10.1001/jamapsychiatry.2024.4789  Aron L et al. Lithium deficiency and the onset of Alzheimer's disease. Nature 2025;645:712–21. doi: 10.1038/s41586-025-09335-x  Never miss an episode!

In this episode, Dr. Andy Cutler talks with Dr. Ryan Sultán about the evolving landscape of ADHD—why diagnoses and prescriptions have risen across age groups, what recent prescribing data reveal, and how these trends align with real-world clinical experience. They explore how ADHD medications affect not just symptoms but broader outcomes like school, work, and safety, while also addressing concerns about overdiagnosis, misuse, and disparities in access to care.   Dr. Ryan Sultan is a board-certified adult and child psychiatrist specializing in attention-deficit/hyperactivity disorder (ADHD) and assistant professor at Columbia University Irving Medical Center and the New York State Psychiatric Institute. He is the Medical Director of NYC-based Integrative Psychiatry, where he assesses and treats patients using a combination of psychological, social, environmental, and pharmacological modalities. Integrative Psychiatry also provides ADHD treatment in Miami. As an ADHD psychiatrist, he conducts extensive ADHD research with a focus on using big data to improve ADHD treatment in real world settings, advocating for non-pharmacological interventions such as cognitive behavioral therapy (CBT) for ADHD, coaching, and digital tools as a foundational treatment that precedes or supplements medication. He approaches ADHD treatment with a nuanced understanding of the current misuse and overdiagnosis crisis, and addresses this issue through careful assessment and monitoring.   Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Never miss an episode!

In this episode, Dr. Andy Cutler interviews Dr. Peter Weiden about when and how to switch antipsychotics in schizophrenia, tackling both the pitfalls and opportunities clinicians face in practice. They also explore how xanomeline–trospium has opened the door to treatments beyond dopamine and what this shift means for the future of care.  Peter J. Weiden, MD, is a psychiatrist and internationally recognized expert in the pharmacologic treatment of schizophrenia. His research and clinical work have focused on antipsychotic effectiveness, switching strategies, and medication adherence, with a particular emphasis on optimizing long-term outcomes for patients.   Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Never miss an episode!

In this episode, Dr. Andy Cutler interviews Dr. Dan Singley about the unique challenges men face in recognizing, expressing, and seeking care for their mental health. They explore how norms around masculinity influence help-seeking behavior and contribute to men's heightened risk of suicide. The conversation also highlights the underrecognized issue of paternal perinatal depression, its impact on family dynamics, and strategies clinicians can use to better screen, engage, and support new fathers.  Dr. Daniel Singley, PhD, is a clinical psychologist and expert in men's mental health, with a particular focus on the transition to fatherhood and perinatal mental health for men. He is the founder and director of the Center for Men's Excellence in San Diego, where he provides therapy, consultation, and training centered on men's psychological development and gender-sensitive care.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Resources  The Center for Men's Excellence – menexcel.com  Society for the Psychology of Men and Masculinities – division51.net  Postpartum Support International – postpartum.net  Man Therapy – mantherapy.org  Never miss an episode!

Dr. Nevena Radonjic, psychiatrist and scientist at SUNY Upstate Medical University, shares insight on optimizing the mental health of pregnant and breastfeeding women. She expands upon this case published in Pharmacotherapy of managing ADHD in a breastfeeding mother. Read the full case report at: https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/phar.70035

In this episode, Dr. Andy Cutler interviews Dr. Roger McIntyre about the growing recognition of Long COVID and its wide-ranging neuropsychiatric manifestations. They discuss the role of neuroinflammation in its pathophysiology, the impact of these symptoms on patients' daily functioning, and both current and emerging treatment approaches.  Dr. Roger McIntyre is a globally recognized psychiatrist and psychopharmacologist who holds pivotal roles in academia, research, and leadership. His research primarily focuses on the phenomenology, neurobiology, and development of novel therapeutics for mood disorders. Dr. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Never miss an episode!

In this episode, Dr. Andy Cutler interviews Dr. Pamela Wall about the complex intersection of PTSD and mild traumatic brain injury (mTBI) in veterans. They explore how military culture influences the experience and treatment of trauma, the challenges of distinguishing overlapping symptoms, and evidence-based strategies for assessment and intervention. Tune in for practical insights, clinical pearls, and resource recommendations for improving care in this uniquely vulnerable population.  Pamela Wall, PhD, PMHNP-BC is an associate professor in the College of Nursing at Rosalind Franklin University and maintains a clinical practice at a neuropsychiatric clinic in Fairfax, VA. She has extensive experience working with adult psychiatric mental health populations, and her research has focused on PTSD, mTBI, and sleep disorders in deployed military service members. Dr. Wall served 20 years on active duty as a Nurse Corps Officer in the United States Navy.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Resources  Center for Deployment Psychology   National Center for PTSD  Traumatic Brain Injury Center of Excellence    Never miss an episode!

In this episode, Dr. Andy Cutler interviews Dr. Steven Chan about the evolving role of artificial intelligence (AI) in psychiatry. They explore practical, real-world applications of AI in clinical settings, highlighting both the benefits and limitations of current technologies. The conversation also looks ahead to the future of AI in mental health care as advancements continue to accelerate.  Steven Chan, MD, MBA, is a clinical informaticist and psychiatrist, as well as a Clinical Assistant Professor at the Stanford University School of Medicine. He is also the Chief Technology Officer and co-founder of AsyncHealth. Dr. Chan's research focuses on telepsychiatry and digital mental health.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Resources  Readiness Evaluation for Artificial Intelligence (READI)  APA App Advisor  Never miss an episode!

In this episode, Dr. Andy Cutler and Dr. Jeffrey Strawn explore the complexities of obsessive-compulsive disorder (OCD). Join the conversation as they discuss how OCD presents across different patients, evidence-based treatment approaches, and the critical role clinicians play in helping individuals manage symptoms and work toward remission.  Jeffrey R. Strawn, MD, FAACAP is a Professor of Psychiatry, Pediatrics, and Clinical & Translational Pharmacology at the University of Cincinnati (UC) in Cincinnati, Ohio. He is the Director of the UC Anxiety Disorders Research Program and the Associate Vice Chair of Research in the Department of Psychiatry & Behavioral Neuroscience at UC.  Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Never miss an episode!

Today, Dr. Andy Cutler interviews Dr. Katharine Phillips about identifying and treating body dysmorphic disorder (BDD). Join the discussion as they talk about how BDD presents, the treatments available for this debilitating disorder, and how clinicians can help their patients reach remission.  Katharine Phillips, MD is a renowned psychiatrist and leading authority on body dysmorphic disorder (BDD). She serves as Professor of Psychiatry and DeWitt Wallace Senior Scholar at Weill Cornell Medical College and is an attending psychiatrist at New York-Presbyterian Hospital.   Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.    Resources  BDD Treatment Manuals International OCD Foundation - BDD     Never miss an episode!

In this episode, Dr. Andy Cutler is joined by Dr. Jennifer Payne to discuss management of mood disorders influenced by fluctuations in reproductive hormones, particularly in women. They explore medication management during the perinatal period, emphasizing the risks associated with inadequately treated mood disorders. The conversation also addresses strategies for managing hormone-related mood disorders across reproductive stages, including premenstrual dysphoric disorder, premenstrual exacerbation, and perimenopausal depression. Jennifer L. Payne, MD is a psychiatrist specializing in reproductive psychiatry and mood disorders in women. She serves as Vice Chair of Research and Professor in the Department of Psychiatry and Neurobehavioral Sciences at the University of Virginia, directing the Reproductive Psychiatry Research Program.  Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.

Join Dr. Andy Cutler and Dr. Cynthia Bulik as they discuss the challenges of diagnosing and treating binge eating disorder (BED). They explore the genetics, neurobiology, and clinical course of BED that inform treatment decisions, and examine how advances in genetic research and emerging pharmacological options may improve outcomes for individuals with BED.  Cynthia Bulik, PhD, FAED is a Distinguished Professor of Eating Disorders in the Department of Psychiatry, a Professor of Nutrition in the Gillings School of Global Public Health and the Founding Director of the Center of Excellence for Eating Disorders at the University of North Carolina at Chapel Hill.    Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.    Resources  Eating Disorders Genetics Initiative (EDGI) 2 - edgi2.org  National Eating Disorders Association - nationaleatingdisorders.org  Families Empowered and Supporting the Treatment of Eating Disorders (FEAST) - feast-ed.org   

Join Dr. Andy Cutler and Dr. Carla Sharp as they discuss the current conceptualization of borderline personality disorder (BPD), including diagnostic challenges, evidence-based treatments, and strategies to reduce stigma by framing BPD as a treatable condition. The conversation also covers recent updates to the APA's BPD guidelines.  Carla Sharp, PhD is a distinguished clinical psychologist specializing in developmental psychopathology, particularly borderline personality disorder (BPD). She is a professor in the Clinical Psychology Doctoral Program and serves as the Associate Dean for Faculty and Research at the University of Houston. Additionally, she directs both the Adolescent Diagnosis, Assessment, Prevention, and Treatment Center and the Developmental Psychopathology Lab at the university.   Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.   

Our first ever repeat guest is Rachel Fabi, PhD, Associate Professor of Bioethics and Humanities at SUNY Upstate Medical University. She is a Faculty Research Affiliate at the Syracuse University Lerner Center for Public Health Promotion. She received her Ph.D. in Health Policy and Management, in the Bioethics and Health Policy track, at the Johns Hopkins Bloomberg School of Public Health, and served as the 2019-2021 National Academy of Medicine Greenwall Fellow in Bioethics. Dr. Fabi had previously joined us in September of 2023, on Season 5 Episode 2 of Bioethics in the Margins. She joins again today to discuss the timely topic of the effect of recent Executive Orders rescinding the 2021 guidance designating schools, churches and healthcare institutions as "safe zones" exempt from immigration enforcement. Dr. Fabi outlines specific strategies that institutions can adopt to protect students and patients, particularly designating areas clearly as private spaces, which require a judicial warrant for ICE agents to enter. She highlights the importance of proactive planning on the part of institutions. Kirk, Amelia and Dr. Fabi reflect on our moral obligations towards immigrants as a society and the specific obligations of ethicists in practice and discuss the importance of immigrant communities to the fabric of our society. Several resources that were mentioned in the episode are linked below:1. Toolkit for healthcare institutions curated by Mark Kuczewski2. Link to “red cards” to inform people of their rights3. Immigration Policy Tracking Project4. The Health of Newcomers by Patricia Illingworth and Wendy E. Parmet

Join Dr. Andy Cutler as he speaks with Dr. Anita Clayton about one of the most common yet least discussed side effects of psychotropic medications—sexual dysfunction. They explore the different aspects of sexual dysfunction that may arise as a side effect, how to distinguish these from symptoms of psychiatric or medical disorders, and how to collaborate with patients to effectively address this challenging issue.  Anita H. Clayton, MD, Wilford W. Spradlin Professor and Chair of Psychiatry & Neurobehavioral Sciences, and Professor of Clinical Obstetrics & Gynecology at the University of Virginia School of Medicine, has focused her research on major depressive disorder, mood disorders associated with reproductive-life events in women (reproductive psychiatry), sexual dysfunction related to illness and medications, and the assessment and treatment of primary sexual disorders.    Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.    Resources  Changes in Sexual Functioning Questionnaire short- form (CSFQ-14)  Validation study for CSFQ-14   

In the second episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we're speaking with Dr. Erin Crane who will highlight how HRD testing provides helpful information to ovarian cancer patients.   Erin K. Crane, MD, MPH, is a gynecologic oncologist with Atrium Health Levine Cancer in Charlotte, North Carolina. A graduate of the SUNY Upstate Medical University in Syracuse, NY, Dr. Crane completed her residency at the University of Virginia and a fellowship at The University of Texas MD Anderson Cancer Center in Gynecologic Oncology. She is board certified by the American Board of Obstetrics and Gynecology in Gynecologic Oncology and Obstetrics and Gynecology. Dr. Crane is a Clinical Associate Professor of Obstetrics and Gynecology at the Wake Forest University School of Medicine.   For more information, visit https://www.azprecisionmed.com/tumor-type/ovarian-cancer/hrd-testing.html For patient resources, please visit TestForHRD.com.   This podcast does not necessarily reflect the opinions of AstraZeneca and are the spokesperson's opinions and experience.

Join Dr. Andy Cutler as he speaks with Dr. Christine Moutier about the unintended effects of the FDA boxed warnings on antidepressant use in pediatric patients—specifically, the underdiagnosis and undertreatment of depression. Their conversation highlights the importance of effectively treating depression to reduce suicide across the lifespan.  Christine Yu Moutier, MD is a leading psychiatrist and the Chief Medical Officer at the American Foundation for Suicide Prevention (AFSP). Since joining AFSP in 2013, Dr. Moutier has led a nationwide movement combining scientific research and grassroots efforts to reduce suicide rates. She has testified before Congress, presented at the White House, and frequently contributes to major media outlets on mental health issues.   Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.    Resources  American Foundation for Suicide Prevention - https://afsp.org/    Save $100 on registration for 2025 NEI Spring Congress with code NEIPOD25  Register today at nei.global/spcongress25f    Never miss an episode!

In the second episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we’re speaking with Dr. Erin Crane who will highlight how HRD testing provides helpful information to ovarian cancer patients. Erin K. Crane, MD, MPH, is a gynecologic oncologist with Atrium Health Levine Cancer in Charlotte, North Carolina. A graduate of the SUNY Upstate Medical University in Syracuse, NY, Dr. Crane completed her residency at the University of Virginia and a fellowship at The University of Texas MD Anderson Cancer Center in Gynecologic Oncology. She is board certified by the American Board of Obstetrics and Gynecology in Gynecologic Oncology and Obstetrics and Gynecology. Dr. Crane is a Clinical Associate Professor of Obstetrics and Gynecology at the Wake Forest University School of Medicine. For more information, visit https://www.azprecisionmed.com/tumor-type/ovarian-cancer/hrd-testing.html For patient resources, please visit TestForHRD.com. This podcast does not necessarily reflect the opinions of AstraZeneca and are the spokesperson's opinions and experience.

In the second episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we’re speaking with Dr. Erin Crane who will highlight how HRD testing provides helpful information to ovarian cancer patients. Erin K. Crane, MD, MPH, is a gynecologic oncologist with Atrium Health Levine Cancer in Charlotte, North Carolina. A graduate of the SUNY Upstate Medical University in Syracuse, NY, Dr. Crane completed her residency at the University of Virginia and a fellowship at The University of Texas MD Anderson Cancer Center in Gynecologic Oncology. She is board certified by the American Board of Obstetrics and Gynecology in Gynecologic Oncology and Obstetrics and Gynecology. Dr. Crane is a Clinical Associate Professor of Obstetrics and Gynecology at the Wake Forest University School of Medicine. For more information, visit https://www.azprecisionmed.com/tumor-type/ovarian-cancer/hrd-testing.html For patient resources, please visit TestForHRD.com. This podcast does not necessarily reflect the opinions of AstraZeneca and are the spokesperson's opinions and experience.

Join Dr. Andy Cutler as he talks with Dr. Jeffrey Strawn about how clinicians can determine the appropriate scenarios for benzodiazepine deprescribing, best practices for benzodiazepine tapering, and how to balance patient preferences to ensure best outcomes.  Jeffrey R. Strawn, MD is a Professor and Associate Vice Chair of Research in the Department of Psychiatry and Behavioral Neuroscience at the University of Cincinnati (UC) College of Medicine, the Assistant Director of Clinical and Translational Research in the Center for Clinical & Translational Science and Training at UC, and an Associate Professor in the Department of Pediatrics at UC and Cincinnati Children's Hospital Medical Center.   Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Save $100 on registration for 2025 NEI Spring Congress with code NEIPOD25  Register today at nei.global/spcongress25p  Never miss an episode!

In this episode, Dr. Robert Corona, CEO of SUNY Upstate Medical University, shares insights on the institution's growth, its strategic goals for 2025, and its efforts to enhance patient access and quality care. He discusses key initiatives, including the adoption of Lean Six Sigma principles and the expansion of access points in response to the region's increasing healthcare demands.

In this episode, Christopher Tanski, MD, MSEd - Associate Chief Medical Officer at SUNY Upstate Medical University, discusses the transformative potential of AI in clinical and operational settings, the promise of hospital-at-home programs, and the evolving landscape of healthcare delivery. He also shares his leadership goals for 2025, focusing on fostering efficiency and innovation in a dynamic healthcare environment.

To donate to my PayPal (thank you): https://paypal.me/danieru22?country.x=US&locale.x=en_US I apologize for any poor audio and no video. We had technical difficulties. I hope you enjoy the conversation, nonetheless. Dr Pies is Professor Emeritus of Psychiatry and Lecturer on Bioethics and Humanities, SUNY Upstate Medical University; Clinical Professor of Psychiatry, Tufts University School of Medicine; and Editor in Chief Emeritus of Psychiatric Times (2007-2010). Dr Pies is the author of several books. Amazon: https://www.amazon.com/stores/Ronald-W.-Pies/author/B001HCU3SY?ref=ap_rdr&isDramIntegrated=true&shoppingPortalEnabled=true&ccs_id=a7c6f7ea-8218-47ac-8e44-552060df69b4 Psychiatric Times: https://www.psychiatrictimes.com/authors/ronald-w-pies-md Note: Information contained in this video is for educational purposes only and is not intended as a substitute for treatment or consultation with a mental health professional or business consultant.

******Support the channel****** Patreon: https://www.patreon.com/thedissenter PayPal: paypal.me/thedissenter PayPal Subscription 5 Dollars: https://tinyurl.com/ycmr9gpz PayPal Subscription 10 Dollars: https://tinyurl.com/y9r3fc9m PayPal Subscription 20 Dollars: https://tinyurl.com/y95uvkao   ******Follow me on****** Website: https://www.thedissenter.net/ The Dissenter Goodreads list: https://shorturl.at/7BMoB Facebook: https://www.facebook.com/thedissenteryt/ Twitter: https://x.com/TheDissenterYT   This show is sponsored by Enlites, Learning & Development done differently. Check the website here: http://enlites.com/   Dr. L. Syd M. Johnson is a philosopher/bioethicist/neuroethicist, a Clinical Ethics Consultant, and Associate Professor of Bioethics and Humanities at SUNY Upstate Medical University. She is a member of the Neuroethics Working Group of the NIH BRAIN Initiative, Associate Editor for Neuroethics, and the co-founder of the American Society for Bioethics + Humanities Animal Bioethics Affinity Group. Her research focuses on ethical issues related to brain injuries, including sport-related neurotrauma, brain death, and disorders of consciousness. She is the author of Philosophical, Medical, and Legal Controversies About Brain Death.   In this episode, we focus on Philosophical, Medical, and Legal Controversies About Brain Death. We tackle the concept of “death” from a medical and legal perspective, and how it is commonly understood. We explore how the concept of “brain death” evolved over time, the different types of brain death, brain-body dualism in medicine, and the metaphysical and moral commitments behind brain death. We go through epistemic, medical, and ethical challenges to brain death. We discuss what happens when there is conflict in worldviews between patients and doctors, and the value of patient autonomy. Finally, we talk about reasonable objections to the medical view of death. -- A HUGE THANK YOU TO MY PATRONS/SUPPORTERS: PER HELGE LARSEN, JERRY MULLER, BERNARDO SEIXAS, ADAM KESSEL, MATTHEW WHITINGBIRD, ARNAUD WOLFF, TIM HOLLOSY, HENRIK AHLENIUS, FILIP FORS CONNOLLY, ROBERT WINDHAGER, RUI INACIO, ZOOP, MARCO NEVES, COLIN HOLBROOK, PHIL KAVANAGH, SAMUEL ANDREEFF, FRANCIS FORDE, TIAGO NUNES, FERGAL CUSSEN, HAL HERZOG, NUNO MACHADO, JONATHAN LEIBRANT, JOÃO LINHARES, STANTON T, SAMUEL CORREA, ERIK HAINES, MARK SMITH, JOÃO EIRA, TOM HUMMEL, SARDUS FRANCE, DAVID SLOAN WILSON, YACILA DEZA-ARAUJO, ROMAIN ROCH, DIEGO LONDOÑO CORREA, YANICK PUNTER, CHARLOTTE BLEASE, NICOLE BARBARO, ADAM HUNT, PAWEL OSTASZEWSKI, NELLEKE BAK, GUY MADISON, GARY G HELLMANN, SAIMA AFZAL, ADRIAN JAEGGI, PAULO TOLENTINO, JOÃO BARBOSA, JULIAN PRICE, EDWARD HALL, HEDIN BRØNNER, DOUGLAS FRY, FRANCA BORTOLOTTI, GABRIEL PONS CORTÈS, URSULA LITZCKE, SCOTT, ZACHARY FISH, TIM DUFFY, SUNNY SMITH, JON WISMAN, WILLIAM BUCKNER, PAUL-GEORGE ARNAUD, LUKE GLOWACKI, GEORGIOS THEOPHANOUS, CHRIS WILLIAMSON, PETER WOLOSZYN, DAVID WILLIAMS, DIOGO COSTA, ALEX CHAU, AMAURI MARTÍNEZ, CORALIE CHEVALLIER, BANGALORE ATHEISTS, LARRY D. LEE JR., OLD HERRINGBONE, MICHAEL BAILEY, DAN SPERBER, ROBERT GRESSIS, IGOR N, JEFF MCMAHAN, JAKE ZUEHL, BARNABAS RADICS, MARK CAMPBELL, TOMAS DAUBNER, LUKE NISSEN, KIMBERLY JOHNSON, JESSICA NOWICKI, LINDA BRANDIN, GEORGE CHORIATIS, VALENTIN STEINMANN, PER KRAULIS, ALEXANDER HUBBARD, BR, MASOUD ALIMOHAMMADI, JONAS HERTNER, URSULA GOODENOUGH, DAVID PINSOF, SEAN NELSON, MIKE LAVIGNE, JOS KNECHT, LUCY, MANVIR SINGH, PETRA WEIMANN, CAROLA FEEST, MAURO JÚNIOR, 航 豊川, TONY BARRETT, BENJAMIN GELBART, NIKOLAI VISHNEVSKY, STEVEN GANGESTAD, AND TED FARRIS! A SPECIAL THANKS TO MY PRODUCERS, YZAR WEHBE, JIM FRANK, ŁUKASZ STAFINIAK, TOM VANEGDOM, BERNARD HUGUENEY, CURTIS DIXON, BENEDIKT MUELLER, THOMAS TRUMBLE, KATHRINE AND PATRICK TOBIN, JONCARLO MONTENEGRO, AL NICK ORTIZ, NICK GOLDEN, AND CHRISTINE GLASS! AND TO MY EXECUTIVE PRODUCERS, MATTHEW LAVENDER, SERGIU CODREANU, BOGDAN KANIVETS, ROSEY, AND GREGORY HASTINGS!

Hey Team! This week, we've got an incredible guest, Dr. Stephen Faraone, one of the world's foremost experts on ADHD. Let me just give you a quick rundown of just how influential Dr. Faraone is: He has authored over 700 journal articles, editorials, chapters, and books Listed as the eighth-highest producer of High Impact Papers in Psychiatry from 1990 to 1999 as determined by the Institute for Scientific Information (ISI). In 2005, the ISI listed him as the second-highest cited author in the area of ADHD. In 2019 and 2020, his citation metrics placed him in the top 0.01% of scientists across all fields. In 2002 he was inducted into the CHADD Hall of Fame Currently, Dr. Faraone serves as a distinguished professor of psychiatry, physiology, and neuroscience at SUNY Upstate Medical University and president of the World Federation of ADHD. So yeah, this guy knows what he's talking about when it comes to ADHD and if you only listen to one episode of the podcast this year, I'd suggest this one. One of the focal points in this conversation is the ADHD Evidence Project, which Dr. Faraone started to help fight misinformation about ADHD and give free access to the information we have about ADHD. On the site - which can be found at ADHDevidence.org - you can find the International Consensus Statement, which provides 208 statements strongly supported by ADHD research. In the episode we get more into what went into the process of making the statement and the standards of research. In the episode, we also discuss evidence-based treatments, debunk common myths, and discuss what really works when managing ADHD. If you'd life to follow along on the show notes page you can find that at HackingYourADHD.com/202 This Episode's Top Tips Stick to treatments that have been proven effective through rigorous studies. Large studies and meta-analyses are more reliable than small studies when determining ADHD treatments. Not all ADHD treatments you find online are helpful—be cautious of sources that aren't peer-reviewed. Beware of misinformation as well as misleading information that can lead you down the wrong treatment path. While some alternative treatments may help, their effects are often significantly smaller compared to standard stimulant medication. When thinking about approaching what we do to help manage our ADHD, we want to think about the magnitude of the effect and do the things that will help the most first.

BUFFALO, NY- October 16, 2024 – A new #review was #published in Oncotarget's Volume 15 on October 1, 2024, entitled, “Molecular chaperones: Guardians of tumor suppressor stability and function.” As highlighted in the abstract of this paper, "tumor suppressor" describes a diverse set of genes typically involved in suppressing metastasis, but which can lead to tumorigenesis when loss-of-function mutations occur. Despite the varied structures and functions of tumor suppressor proteins, many share a common regulatory mechanism—they are "clients" of molecular chaperones, and they rely on an intracellular network of chaperones and co-chaperones to maintain their stability. Mutations in tumor suppressors that disrupt proper chaperoning prevent cells from maintaining sufficient protein levels for normal physiological function. In their review, researchers Jennifer A. Heritz, Sarah J. Backe, and Mehdi Mollapour from SUNY Upstate Medical University and New York VA Health Care in Syracuse, New York, discuss the role of molecular chaperones Hsp70 and Hsp90 in maintaining the stability and functional integrity of tumor suppressors. They also detail the contributions of co-chaperones prefoldin, HOP, Aha1, p23, FNIP1/2, and Tsc1, as well as the chaperonin TRiC, to tumor suppressor stability. “Overall, it is clear that oncogenesis can result from the dysregulation of tumor suppressor stabilization by chaperones.” DOI - https://doi.org/10.18632/oncotarget.28653 Correspondence to - Mehdi Mollapour - mollapom@upstate.edu Video short - https://www.youtube.com/watch?v=V5OFjeqaH3A Sign up for free Altmetric alerts about this article: https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28653 Subscribe for free publication alerts from Oncotarget: https://www.oncotarget.com/subscribe/ Keywords - cancer, molecular chaperone, tumor suppressor, renal cell carcinoma, Birt-Hogg-Dubé (BHD) syndrome, TSC syndrome About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Dr. Khanum, Dr. Aida or Dr. K as some patients call her has lived in Houston since 2003. She completed her residency in Pediatrics at SUNY Upstate Medical University in Syracuse, New York. She continued her training by completing a Fellowship in Academic General Pediatrics at Baylor College of Medicine. Simultaneously, she completed a Masters in Public Health from UT School of Public Health. She has practiced in the Greater Houston area as a Board-Certified Pediatrician since the completion of her training in 2003. Through her more than 20 years of experience, she has seen first-hand how parents juggle their personal and professional lives. She found a need for a pediatric clinic that was in an easily accessible location within one of the busiest hubs of Houston – the City of Bellaire. This need, along with her desire to establish a practice with a neighborhood feel, led to the creation of Pediatric Pod. Dr. Aida Khanum is a mother to 3 active young boys and lives with her husband and family in the City of Bellaire. She is involved in the local school and community. She speaks multiple languages including Spanish, German, Urdu and Hindi. She has travelled to various parts of the world – Southeast Asia, the Middle East, Africa, Europe and Central America – but is very proud to call Houston her home. Dr. Aida Khanum stands out with her experience, wealth of knowledge, and desire to provide the best loving care possible for her patients. Connect on Social Media Pediatricpod on all platforms

BUFFALO, NY- August 15, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on August 14, 2024, entitled, “A nanobody against the V-ATPase c subunit inhibits metastasis of 4T1-12B breast tumor cells to lung in mice.” The vacuolar H+-ATPase (V-ATPase) is an ATP-dependent proton pump that functions to control the pH of intracellular compartments as well as to transport protons across the plasma membrane of various cell types, including cancer cells. Researchers Zhen Li, Mohammed A. Alshagawi, Rebecca A. Oot, Mariam K. Alamoudi, Kevin Su, Wenhui Li, Michael P. Collins, Stephan Wilkens, and Michael Forgac from Tufts University School of Medicine; Tufts University; Dana Farber Cancer Institute, Harvard Medical School; University of Minnesota School of Medicine; Prince Sattam Bin Abdulaziz University; Korro Bio; SUNY Upstate Medical University; and Foghorn Therapeutics, have previously shown that selective inhibition of plasma membrane V-ATPases in breast tumor cells inhibits the invasion of these cells in vitro. They have now developed a nanobody directed against an extracellular epitope of the mouse V-ATPase c subunit. “We show that treatment of 4T1-12B mouse breast cancer cells with this nanobody inhibits V-ATPase-dependent acidification of the media and invasion of these cells in vitro.” The research team further found that injecting this nanobody into mice implanted with 4T1-12B cells orthotopically in the mammary fat pad inhibited the metastasis of tumor cells to the lungs. “In conclusion, our results indicate that a nanobody directed against an extracellular epitope expressed on the surface of the V-ATPase is able to inhibit activity of cell surface V-ATPases in 4T1-12B breast cancer cells, inhibit in vitro invasion of these cells and inhibit metastasis of these cells to lung following their implantation in the mammary fat pad of mice.” DOI - https://doi.org/10.18632/oncotarget.28638 Correspondence to - Michael Forgac - michael.forgac@tufts.edu Video short - https://www.youtube.com/watch?v=4eLGqvSfAgg Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28638 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, vacuolar ATPase, breast cancer, invasion, tumor metastasis, tumor growth About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Elon Musk's project Neuralink has been bringing a concept that seems out of science fiction, brain implants that allow users to control tech, into reality. So far, the company has implanted the device into a subject with quadriplegia. While he was able to do things like play online chess, he then lost some of the ability when parts of the device slipped out of place. This all begs questions about safety, ethics and the future of the human relationship with technology. Our team at “Something Offbeat” reached out to two experts – L. Syd M. Johnson, associate professor of bioethics and humanities at SUNY Upstate Medical University, and science journalist Faye Flam – to dive into them.

Dr. Robert Gregory discusses his Dynamic Deconstructive Psychotherapy (DDP) and Psychiatry High Risk Program, an evidence based alternative to dialectical behaviour therapy for people with borderline personality disorder. He also shares his insights on a concept of "embedded badness", the neuroscience behind BPD, and the impacts of academia on promising new treatment options. Dr. Robert Gregory is a Professor of Psychiatry at SUNY Upstate Medical University. He is the developer of an evidence-based treatment for borderline personality disorder called Dynamic Deconstructive Psychotherapy and is the founder of the Psychiatry High Risk Program, a recovery-based suicide prevention program for adolescents and young adults that uses Dynamic Deconstructive Psychotherapy as its core treatment.To find out more about Dynamic Deconstructive Therapy including handouts click here.Send us a Text Message.Support the Show.You can find Laurie and Sara on Instagram to follow their day to day lives even further @laurieanned and @saraswellnessway. You can also find the podcast on IG @boldbeautifulborderline Leave us a voicemail about your thoughts on the show at boldbeautifulborderline.comRegister for our free peer support group at https://www.eventbrite.ca/e/the-super-feelers-club-tickets-145605434775Register for our low-barrier drop-in DBT group at https://www.thewellnesswayllc.comPurchase the Exploring Your Borderline Strengths Journal at https://www.amazon.com/Exploring-Your-Borderline-Strengths-Amundson/dp/B0C522Y7QT/ref=sr_1_1?crid=IGQBWJRE3CFX&keywords=exploring+your+borderline+strengths&qid=1685383771&sprefix=exploring+your+bor%2Caps%2C164&sr=8-1 If you like the show we would love if you could rate, subscribe and support us on Patreon. Patreon info here: https://www.patreon.com/boldbeautifulborderline?fan_landing=true ...